Skip to main content

Remote Job Finders (RJF)

Kezar Loses 70% of Staff After FDA Cancels Meeting on Autoimmune Asset

Kezar Life Sciences suffered multiple clinical holds and four patient deaths in a trial testing zetomipzomib for lupus—a program that has since been canned. The company is still pursuing development in autoimmune hepatitis, but recent FDA communications could delay its timeline.

Despite Obesity Drug Pricing Deal, GLP-1 Compounders Continue To Operate in the Shadows

The White House may have struck a deal with Eli Lilly and Novo Nordisk last week to lower the costs of their weight loss drugs for patients, but knockoff versions of Zepbound and Wegovy still permeate the obesity market.
Scroll to top